Is DNA or GNLX more profitable?

Genelux has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Ginkgo Bioworks' return on equity of -56.08% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Ginkgo Bioworks -215.41% -56.08% -26.06% Genelux N/A -174.55% -123.65%

Which has preferable valuation & earnings, PRME or GNLX?

Genelux has lower revenue, but higher earnings than Prime Medicine. Genelux is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prime Medicine $4.63M 126.39 -$201.14M -$1.23 N/A Genelux $10K 13,093.28 -$32.15M -$0.85 N/A

Is PRME or GNLX more profitable?

Genelux has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Genelux's return on equity of -174.55% beat Prime Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Prime Medicine -4,917.55% -188.82% -60.97% Genelux N/A -174.55% -123.65%

Which has higher earnings and valuation, GNLX or PROK?

Genelux has higher earnings, but lower revenue than ProKidney. Genelux is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genelux $10K 13,093.28 -$32.15M -$0.85 N/A ProKidney $890K 610.91 -$68.99M -$0.53 N/A

Is GNLX or PROK more profitable?

Genelux has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Genelux N/A -174.55% -123.65% ProKidney -8,131.50% N/A -21.39%

Which has higher valuation and earnings, GNLX or ALT?

Genelux has higher earnings, but lower revenue than Altimmune. Genelux is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genelux $10K 13,093.28 -$32.15M -$0.85 N/A Altimmune $36K 15,719.98 -$88.09M -$0.93 N/A

Is GNLX or ALT more profitable?

Genelux has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Genelux N/A -174.55% -123.65% Altimmune -214,860.98% -42.57% -35.57%

Genelux (GNLX) Competitors

$2.92 0.00 (0.00%)

As of 04:00 PM Eastern

Compare

GNLX vs. DNA, AQST, PRME, PROK, and ALT

Should you buy Genelux stock or one of its competitors? MarketBeat compares Genelux with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genelux include Ginkgo Bioworks (DNA), Aquestive Therapeutics (AQST), Prime Medicine (PRME), ProKidney (PROK), and Altimmune (ALT). These companies are all part of the "pharmaceutical products" industry.

How does Genelux compare to Ginkgo Bioworks?

Ginkgo Bioworks (NYSE:DNA) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Genelux has lower revenue, but higher earnings than Ginkgo Bioworks. Genelux is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	3.41	-$312.76M	-$5.36	N/A
Genelux	$10K	13,093.28	-$32.15M	-$0.85	N/A

Ginkgo Bioworks presently has a consensus price target of $8.50, suggesting a potential downside of 4.28%. Genelux has a consensus price target of $18.00, suggesting a potential upside of 516.44%. Given Genelux's stronger consensus rating and higher possible upside, analysts plainly believe Genelux is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Ginkgo Bioworks has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market. Comparatively, Genelux has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

In the previous week, Ginkgo Bioworks' average media sentiment score of 0.00 equaled Genelux'saverage media sentiment score.

Company	Overall Sentiment
Ginkgo Bioworks	Neutral
Genelux	Neutral

Genelux has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Ginkgo Bioworks' return on equity of -56.08% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%
Genelux	N/A	-174.55%	-123.65%

78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 37.3% of Genelux shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by insiders. Comparatively, 7.5% of Genelux shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Ginkgo Bioworks and Genelux tied by winning 7 of the 14 factors compared between the two stocks.

How does Genelux compare to Aquestive Therapeutics?

Genelux (NASDAQ:GNLX) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Genelux has higher earnings, but lower revenue than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	13,093.28	-$32.15M	-$0.85	N/A
Aquestive Therapeutics	$50.27M	12.55	-$83.78M	-$0.61	N/A

Genelux has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market.

37.3% of Genelux shares are owned by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are owned by institutional investors. 7.5% of Genelux shares are owned by company insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Genelux currently has a consensus target price of $18.00, indicating a potential upside of 516.44%. Aquestive Therapeutics has a consensus target price of $8.50, indicating a potential upside of 68.99%. Given Genelux's higher probable upside, research analysts clearly believe Genelux is more favorable than Aquestive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Aquestive Therapeutics had 2 more articles in the media than Genelux. MarketBeat recorded 2 mentions for Aquestive Therapeutics and 0 mentions for Genelux. Genelux's average media sentiment score of 0.00 equaled Aquestive Therapeutics'average media sentiment score.

Company	Overall Sentiment
Genelux	Neutral
Aquestive Therapeutics	Neutral

Genelux has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%. Aquestive Therapeutics' return on equity of 0.00% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-174.55%	-123.65%
Aquestive Therapeutics	-137.08%	N/A	-49.33%

Summary

Aquestive Therapeutics beats Genelux on 9 of the 16 factors compared between the two stocks.

How does Genelux compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and Genelux (NASDAQ:GNLX) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

Prime Medicine presently has a consensus target price of $7.38, suggesting a potential upside of 127.62%. Genelux has a consensus target price of $18.00, suggesting a potential upside of 516.44%. Given Genelux's higher probable upside, analysts clearly believe Genelux is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Prime Medicine had 2 more articles in the media than Genelux. MarketBeat recorded 2 mentions for Prime Medicine and 0 mentions for Genelux. Prime Medicine's average media sentiment score of 0.00 equaled Genelux'saverage media sentiment score.

Company	Overall Sentiment
Prime Medicine	Neutral
Genelux	Neutral

Genelux has lower revenue, but higher earnings than Prime Medicine. Genelux is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	126.39	-$201.14M	-$1.23	N/A
Genelux	$10K	13,093.28	-$32.15M	-$0.85	N/A

Genelux has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Genelux's return on equity of -174.55% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
Genelux	N/A	-174.55%	-123.65%

70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 16.0% of Prime Medicine shares are owned by insiders. Comparatively, 7.5% of Genelux shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Prime Medicine has a beta of 2.31, meaning that its stock price is 131% more volatile than the broader market. Comparatively, Genelux has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

Summary

Prime Medicine beats Genelux on 10 of the 16 factors compared between the two stocks.

How does Genelux compare to ProKidney?

Genelux (NASDAQ:GNLX) and ProKidney (NASDAQ:PROK) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

In the previous week, ProKidney's average media sentiment score of 1.42 beat Genelux's score of 0.00 indicating that ProKidney is being referred to more favorably in the news media.

Company	Overall Sentiment
Genelux	Neutral
ProKidney	Positive

Genelux has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-174.55%	-123.65%
ProKidney	-8,131.50%	N/A	-21.39%

Genelux has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, ProKidney has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market.

Genelux currently has a consensus target price of $18.00, indicating a potential upside of 516.44%. ProKidney has a consensus target price of $7.40, indicating a potential upside of 311.11%. Given Genelux's higher probable upside, analysts plainly believe Genelux is more favorable than ProKidney.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
ProKidney	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

37.3% of Genelux shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 7.5% of Genelux shares are held by company insiders. Comparatively, 39.8% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Genelux has higher earnings, but lower revenue than ProKidney. Genelux is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	13,093.28	-$32.15M	-$0.85	N/A
ProKidney	$890K	610.91	-$68.99M	-$0.53	N/A

Summary

ProKidney beats Genelux on 11 of the 15 factors compared between the two stocks.

How does Genelux compare to Altimmune?

Genelux (NASDAQ:GNLX) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

In the previous week, Altimmune had 3 more articles in the media than Genelux. MarketBeat recorded 3 mentions for Altimmune and 0 mentions for Genelux. Altimmune's average media sentiment score of 0.36 beat Genelux's score of 0.00 indicating that Altimmune is being referred to more favorably in the news media.

Company	Overall Sentiment
Genelux	Neutral
Altimmune	Neutral

37.3% of Genelux shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 7.5% of Genelux shares are owned by company insiders. Comparatively, 1.6% of Altimmune shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Genelux currently has a consensus target price of $18.00, suggesting a potential upside of 516.44%. Altimmune has a consensus target price of $15.71, suggesting a potential upside of 440.01%. Given Genelux's higher probable upside, equities analysts plainly believe Genelux is more favorable than Altimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Altimmune	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55

Genelux has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-174.55%	-123.65%
Altimmune	-214,860.98%	-42.57%	-35.57%

Genelux has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Altimmune has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market.

Genelux has higher earnings, but lower revenue than Altimmune. Genelux is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	13,093.28	-$32.15M	-$0.85	N/A
Altimmune	$36K	15,719.98	-$88.09M	-$0.93	N/A

Summary

Altimmune beats Genelux on 10 of the 16 factors compared between the two stocks.

Get Genelux News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GNLX vs. The Competition

Export

Metric	Genelux	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$130.93M	$3.45B	$6.47B	$12.11B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-3.44	20.09	24.71	24.00
Price / Sales	13,093.28	297.62	519.55	102.13
Price / Cash	N/A	56.54	27.92	37.84
Price / Book	9.73	8.28	10.82	6.53
Net Income	-$32.15M	$23.85M	$3.56B	$336.99M
7 Day Performance	-3.63%	5.21%	1.68%	-0.22%
1 Month Performance	N/A	2.18%	0.44%	0.77%
1 Year Performance	5.42%	60.99%	32.84%	31.57%

Genelux Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GNLX Genelux	1.4425 of 5 stars	$2.92 flat	$18.00 +516.4%	-1.7%	$130.93M	$10K	N/A	10
DNA Ginkgo Bioworks	0.1693 of 5 stars	$8.22 -0.1%	$8.50 +3.4%	+5.6%	$536.80M	$170.15M	N/A	640	Gap Down
AQST Aquestive Therapeutics	1.8488 of 5 stars	$4.26 +0.9%	$8.80 +106.6%	+45.2%	$534.42M	$44.54M	N/A	160	News Coverage Positive News
PRME Prime Medicine	1.6295 of 5 stars	$2.87 -1.0%	$7.65 +166.6%	N/A	$518.38M	$4.63M	N/A	N/A	Analyst Forecast Gap Down
PROK ProKidney	2.4585 of 5 stars	$1.69 +1.2%	$7.40 +337.9%	+175.7%	$510.48M	$890K	N/A	3	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GNLX) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genelux (GNLX) Competitors

GNLX vs. DNA, AQST, PRME, PROK, and ALT

How does Genelux compare to Ginkgo Bioworks?

Summary

How does Genelux compare to Aquestive Therapeutics?

Summary

How does Genelux compare to Prime Medicine?

Summary

How does Genelux compare to ProKidney?

Summary

How does Genelux compare to Altimmune?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNLX vs. The Competition

Genelux Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genelux (GNLX) Competitors

GNLX vs. DNA, AQST, PRME, PROK, and ALT

How does Genelux compare to Ginkgo Bioworks?

Which has stronger valuation & earnings, DNA or GNLX?

Do analysts recommend DNA or GNLX?

Which has more risk and volatility, DNA or GNLX?

Does the media favor DNA or GNLX?

Is DNA or GNLX more profitable?

Do institutionals and insiders have more ownership in DNA or GNLX?

Summary

How does Genelux compare to Aquestive Therapeutics?

Which has higher earnings and valuation, GNLX or AQST?

Which has more volatility & risk, GNLX or AQST?

Do insiders and institutionals believe in GNLX or AQST?

Do analysts recommend GNLX or AQST?

Does the media refer more to GNLX or AQST?

Is GNLX or AQST more profitable?

Summary

How does Genelux compare to Prime Medicine?

Do analysts prefer PRME or GNLX?

Does the media prefer PRME or GNLX?

Which has preferable valuation & earnings, PRME or GNLX?

Is PRME or GNLX more profitable?

Do insiders & institutionals have more ownership in PRME or GNLX?

Which has more volatility and risk, PRME or GNLX?

Summary

How does Genelux compare to ProKidney?

Does the media favor GNLX or PROK?

Is GNLX or PROK more profitable?

Which has more volatility and risk, GNLX or PROK?

Do analysts rate GNLX or PROK?

Do institutionals and insiders believe in GNLX or PROK?

Which has higher earnings and valuation, GNLX or PROK?

Summary

How does Genelux compare to Altimmune?

Does the media favor GNLX or ALT?

Do institutionals & insiders have more ownership in GNLX or ALT?

Do analysts recommend GNLX or ALT?

Is GNLX or ALT more profitable?

Which has more volatility and risk, GNLX or ALT?

Which has higher valuation and earnings, GNLX or ALT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNLX vs. The Competition

Genelux Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools